Chronic myeloid leukemia — before and after imatinib (part II)

1. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845;64:413.

2. Craigie D. Case of disease of the spleen in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1845;64:400.

3. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497—501.

4. Lugo T.G. et al. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079—82.

5. Daley G.Q. et al. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824—30.

6. Deininger M.W. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691—8.

7. Sawyers C.L. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am 1999;5:63—9.

8. Druker B.J. et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3—7.

9. Cowan-Jacob S. et al. Structural biology contributions to the discovery of drugs to treat of chronic myelogenous leukemia. Acta Cristallographica 2007;63;80—93.

10. Druker B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561—6.

11. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001;7:228—34.

12. Geay J.F., Buet D., Zhang Y. et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005;65(7): 2676—83.

13. Barnes K., McIntosh E., Whetton A.D. et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005;24(20):3257—67.

14. Cullinane C., Dorow D.S., Kansara M. et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005;65(21):9633—6.

15. Gambacorti-Passerini C., le Coutre P., Mologni L. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380—94.

16. Le Coutre P., Mologni L., Cleris L. In vivo eradication of human BCR/ABLpositive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1991;91:163—8.

17. Holyoake D.T. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001;113:11—23.

18. Heinrich M.C. et al. Inhibition of c-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925—32.

19. Dewar A.L. et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105(8):3127—32.

20. Buchdunger E. et al. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139—45.

21. Okuda K. et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97(8):244.

22. Breccia M., Stefanizzi C., Cannella L. et al. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma 2008;49(12):2328—32.

23. Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase. Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15:1599—610.

24. Bueso-Ramos C.E. et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101(2): 332—6.

25. Agis H., Jaeger E., Doninger B. et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006;36:402—8.

26. Thiele J., Kvasnicka H.M., Schmitt-Graeff A. et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005;46(5): 540—50.

27. Kvasnicka H.M., Thiele J., Staib P.et al. Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia.Pathologe 2004;25(2):127—34.

28. Weisberg E. et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005;7(2):129—41.

29. Liu Y. et al. Rational design of inhibitors hat bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358—64.

30. O'Hare T. et al. In vitro activity of BCR-ABL inhibitors AMN-107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. Cancer Res 2005;65(11): 4500—5.

31. Stover E.H. et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 2005;106(9):3206—13.

32. Bubnoff von N. et al. The systemic mastocytosis -specific activating c-KIT mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005; Advance online publication 1—2.

33. Weisberg E. et al. AMN 107(nilotinib): a novel and selective inhibitor of bcr-abl. Br J Cancer 2006;94:1130—340.

34. Tokarski J.S. et al. The structure of Dasatinib (BMS354825) bound to activated abl kinase of domain elucidates its inhibitory activity against imatinib-resistant mutants. Cancer Res 2006;66: 5790—7.

35. O’Hare T. et al. In vitro activiy of AMN 107 and BMS354825 against clinically relevant imatinib-resistant abl kinase domain mutants. Cancer Res 2005; 65: 4500—5.

36. Klejman A. et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid cells. EMBO J 2002;21:5766—74.

37. Skorski T. et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3-K/Akt dependent pathway. EMBO J 1997;16:6151—61.

38. Donato N.J. et al. BCR-ABL independence and Lyn kinase overexpression in chronic myeloid leukemia cells selected for resistance to STI571. Blood 2003;101:690—8.

39. Ptasznik A. et al. Short interfering RNA targeting the Lyn kinase indusec apoptosis in primary and drug-resistance BCR-ABL+ cells. Nat Med 2004;10:1187—98.

40. Rix U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 2007;First edition paper: 1—34.

41. Fabarius A. et al. Centrosome aberrations, disturbed mitotic spindle formation and G1 arrest in normal and leukemia cells treated with SRC/ABL inhibitor Dasatinib. Blood 206;108:614—5(a).

42. Larson R. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111(8):4022—8.

43. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69(13):1777—98.

44. Wang Y., Zhou L., Dutreix C. at al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008;65(6):885—92.

45. Orhanos G.S., Joannidis G.N. Cardiotoxicity induced by tyrosine kinase inhibitors. Dep Oncol Acta Oncol 2009;4:1—7.

46. Ridruejo E., Caccione R. et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48): 6608—11.

47. Nikolova Z. et al. Bioequivalence, safety and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004;53:433—8.

48. Deremer D.L., Ustun C., Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008;30(11):1956—75.

49. Kagan M. et al. Safety, pharmacokinetics, metabolism and mass balance of AMN 107, a noval aminopyridine tirosin kinase inhibitor in healthy subjects. Blood 2005;106:302 (abstr 4887).

50. Tanaka C. et al. Clinical pharmacokinetics of AMN107, a novel inhibitor of abl, in healthy subjects and patients with imatinib resistant and intolerant chronic myelogenous leukemia or relapsed/refractory Ph+-acute lymphoblastic leukemia. J Clin Oncol 2006;18(suppl 24):144 (abstr 3095).

51. Novartis pharmaceuticals corporation: East Hanover (NJ). TasignaR (Nilotinib capsules): US prescribing information [Online]. Available from URL: http://www.fda.gov

52. Singer J.B. et al. UGT1A1 promotor polymorphism increases risk of nilotinibinduced hyperbilirubinemia. Leukemia 2007;21:2311—5.

53. Hazarika M. et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or in tolerant of Imatinib. Clin Cancer Res 2008;14(17):5325—31.

54. White D.L. et al. OCT-1 mediated influx is a key determinant of the intercellular uptake of imatinib but not nilotinib: OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108(2):697—704.

55. Brendel C. et al. Imatinibe mesilate and Nilotinib exhibit high-affinity interaction with ABCG2 on primitive hematopoetic stem cells. Leukemia 2007;109(8):3609—10.

56. Davies A. et al. Characterization of nilotinib transport in chronic myeloid leukemia cells. Blood 2007;110:2364 (abstr).

57. Tyler T. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann Pharmacother 2009;43(5):920—7.

58. SprycelR prescribing information. Bristol Myers Squibb. NY, USA. 2007.

59. Giannoudis A., Davies A., Lucas C.M. et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112(8):3348—54.

60. Egorin M.J., Shah D.D., Christner S.M. et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009;68(3):370—4.

61. Quinta’s-Cardama A., Han X., Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114(2):261—3.

62. Hochhaus A., Giles F.J., Baccarani P. et al. Safety and efficacy of Nilotinib dose escalation 600 mg BID in patients with imatinib-resistant or intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis. Blood 2007;110(11):1038.

63. Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15:1599—610.

64. Matsuo E., Miyazaki Y. et al. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan. Int J Hematol 2007;85(2):132—9.

65. Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Sem In Hematol 2003;40(2 suppl 2):21—5.

66. Kantarjian H., Talpaz M. et al. High-dose imatinib mesylate therapy in newly diagnosed philadelphia chromosome positive chronic myeloid leukemia. Blood 2004;103(8):2873—8.

67. Bhargav R., Mahapatra M., Mishra P., Kumar R. Overdose with 6400 mg of imatinib: is it safe? Ann Oncol 2007;18(10):1750—1.

68. Gambacorti-Passerini K. et al. Gynecomastia in men with chronic myeloi leukemia after imatinib. Lancet 2003;361:1954—6.

69. Cerchione C., Fabbricini R., Pane F. et al. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Leuk Res 2009;33(8):104—5.

70. Oztas P., Erbasi S. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia. Acta Derm Venereol 2006;86(2):174—5.

71. Woo S.M., Huh C.H. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol 2007;34(10):724—6.

72. De Arriba J., Nerin C., Garcia E. et al. Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Ann Oncol 2003;14:962.

73. Novaretti M., Fonseca G., Conchon M. et al. First case of immunemediated haemolytic anaemia associated to imatinib mesylate. Eur J Haematol 2003;71:455—8.

74. Cortes J. et al. Efficacy of nilotinib (AMN 107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogelous leukemia in early chronic phase. Blood 2007;110(11):abstr 29.

75. Talpaz M., Shah N.P., Kantarjian H. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531—41.

76. Kantarjian H.M. et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CMLCP) patients with imatinib-resistance or in tolerance. Blood 2007;110:226: abstr 735.

77. Le Coutre P. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540—6.

78. Nicolini F. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:870.

79. Nicolini E.F. et al. Expanding Nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase: preliminary safety analysis. ASCO Annual Meeting 2008: abstr 7059.

80. Cortes J. et al. Nilotinib is associated with minimal cross intolerance in patients with imatinib-intolerant Philadelphia-Positive chronic myelogenous leukemia in either chronic phase or accelerated phase. Blood 2007;110. Abstr 1040.

81. Jabbour E. et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib intolerance chronic myeloid leukemia in chronic phase or accelerated phase. Blood 2008;112(11):abstr 3215.

82. Nicolini E.F. et al. Expanding Nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia: subgroup analysis of patients who failed prior dasatinib therapy. Hematologica 2009;94(2): abstr 633.

83. Stephens J. et al. Haematologica 2007;92(1):abstr 0552.

84. Stephens J. et al. Haematologica 2007;92(1):abstr 0658.

85. Cortes J. et al. Efficacy of dasatinib in patients with previously untreated chronic myelogelous leukemia in early chronic phase. Blood 2007;110(11):abstr 30.

86. Shah N.P. et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerabiliry in imatinib-resistant and intolerant chronic phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):1—9

87. Jayson G.C. et al. Blockade of platelet derived growth factor receptor-beta by CD860, humanized, PEGylated di-Fab', leads to fluid accu,ulation and its association with increased tumor vascularized volume. J Clin Oncol 2005;23:973—81.

88. Punnialingam S., Lavallade H., Bua M. et al. Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immunemediated pathogenesis. Br J Haematol 2008;141:7345—47.

89. Kneidinger M. et al. The effects of dasatinib on IgE receptor dependent activation and histamine release in human basophils. Blood 2008;111:3097—107.

90. Weichsel R. et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14(8):2484—91.

91. Torres H.A. et al. Viral infection or reactication in patients during treatment with dasatinib. Leuk Lymph 2007;48(12):2308—9.

92. Garcia-Munoz R. et al. Pavovirus B19 acute infection and reactivation of cytomegalovirus and herpes virus 6 in a chronic myeloid leukemia patient during treatment with dasatinib. Leukem Lymph 2007;48:2461—4.

93. State and role of Src family kinases in replication of herpes simplex virus 1. J Virol 2006;80:3349—59.

94. Quintas-Cardama A. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908—13.

95. Nicaise C. et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Hematologica 2008;93(1): abstr 0559.

96. Bargeon A. et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Respirat Critic Care Med 2007;176:814—8.

97. Quintas-Cardama A. et.al. Association of pleural effusion and bleeding in patients with chronic myelogenous leukemia receiving dasatinib. ASH 2008;abstr 2112.

98. Hochhaus A. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 1—7.

99. Quintas-Cardama A. et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115(11): 2482—90.

100. Rizzo J.D. et al. Use of epoetin and darbopoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update. Blood 2008;111:25—41.

101. Pye S.M. et al. The effects of imatinib on pregnancy outcome. Blood 2008;111(12):5505—8.

102. Gschwing H.P. et al. Drug metab dispos 2008;33(10):1902—12.

103. Rousselot P. et al. Imatinib mesylate discontinuation inpatients with chronic myeloid leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58—60.

104. Russel M.A. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007;27:241—3.

105. Hansley M.L. et al. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Sem Hematol 2003;40:21—5.

106. Gambacorti-Passerini C. et al. Gynecomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003;363:1954—6.

107. Ramasamy K. et al. Successful pregnancies involving men with chronic myeloid leukemia on imatinib therapy. Br J Haematol 2007;137:374—5.

108. Ault P. et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204—8.

109. Breccia M. et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008;32:519—20.

110. Sette C. et al. The role of stem cell factor and of alternative c-KIT gene products in the establishment, maintenance and function of germ cells. Int J Dev Biol 2002;44:599—608

111. Basciani S. et al. Expression of PDGF-A, PDGF-B and PDGFR-alpha and PDGFR-beta during human testicular development and disease. J Clin Endocrinol Metab 2002;87: 2310—9.

112. Jabbour E., Hochaus A., Cortes J. et al. Choosing the best treatment strategy for chronic myeloid leukemia patients, resistant to imatinib: weighing the efficacy and safety of individual drugs with BCRABL murtations and patient history. Leukemia 2009; Oct 1 [Epub ahead of print].